Tags

Type your tag names separated by a space and hit enter

Statins and primary liver cancer: a meta-analysis of observational studies.
Eur J Cancer Prev. 2013 May; 22(3):229-34.EJ

Abstract

Statins are among the most commonly prescribed drugs used to manage dyslipidemia. Hepatocellular carcinoma is the third leading cause of cancer mortality and its rates have recently been increasing in central and northern Europe and USA. To quantify the association between statin use and risk for HCC, we performed a meta-analysis of published studies. We conducted a MEDLINE search for observational studies reporting the association between exposure to statins and risk for incident liver cancer until March 2012. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Moreover, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Five observational studies (two case-control and three cohort studies) based on 2574 cases of HCC were included. Statin treatment, compared with no treatment, was inversely related to HCC (summary RR=0.58; 95% CI 0.46-0.74). Between-study heterogeneity was significant (P<0.001) and numerically relevant (I=65%). When only longest statin use was considered, the RR was 0.66 (95% CI 0.55-0.80). Influence analysis on the overall estimate showed that heterogeneity was largely because of one study; when omitting it, the I dropped to 27% (P=0.240), whereas the summary RR was only marginally modified (RR=0.52; 95% CI 0.44-0.62). There was no evidence of publication bias. This meta-analysis suggests a favorable effect of statins on HCC, in the absence, however, of a duration-risk relationship.

Authors+Show Affiliations

Department of Statistics, Units of Biostatistics and Epidemiology, University of Milano-Bicocca, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23010949

Citation

Pradelli, Danitza, et al. "Statins and Primary Liver Cancer: a Meta-analysis of Observational Studies." European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), vol. 22, no. 3, 2013, pp. 229-34.
Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev. 2013;22(3):229-34.
Pradelli, D., Soranna, D., Scotti, L., Zambon, A., Catapano, A., Mancia, G., La Vecchia, C., & Corrao, G. (2013). Statins and primary liver cancer: a meta-analysis of observational studies. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), 22(3), 229-34. https://doi.org/10.1097/CEJ.0b013e328358761a
Pradelli D, et al. Statins and Primary Liver Cancer: a Meta-analysis of Observational Studies. Eur J Cancer Prev. 2013;22(3):229-34. PubMed PMID: 23010949.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statins and primary liver cancer: a meta-analysis of observational studies. AU - Pradelli,Danitza, AU - Soranna,Davide, AU - Scotti,Lorenza, AU - Zambon,Antonella, AU - Catapano,Alberico, AU - Mancia,Giuseppe, AU - La Vecchia,Carlo, AU - Corrao,Giovanni, PY - 2012/9/27/entrez PY - 2012/9/27/pubmed PY - 2013/12/24/medline SP - 229 EP - 34 JF - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JO - Eur. J. Cancer Prev. VL - 22 IS - 3 N2 - Statins are among the most commonly prescribed drugs used to manage dyslipidemia. Hepatocellular carcinoma is the third leading cause of cancer mortality and its rates have recently been increasing in central and northern Europe and USA. To quantify the association between statin use and risk for HCC, we performed a meta-analysis of published studies. We conducted a MEDLINE search for observational studies reporting the association between exposure to statins and risk for incident liver cancer until March 2012. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Moreover, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Five observational studies (two case-control and three cohort studies) based on 2574 cases of HCC were included. Statin treatment, compared with no treatment, was inversely related to HCC (summary RR=0.58; 95% CI 0.46-0.74). Between-study heterogeneity was significant (P<0.001) and numerically relevant (I=65%). When only longest statin use was considered, the RR was 0.66 (95% CI 0.55-0.80). Influence analysis on the overall estimate showed that heterogeneity was largely because of one study; when omitting it, the I dropped to 27% (P=0.240), whereas the summary RR was only marginally modified (RR=0.52; 95% CI 0.44-0.62). There was no evidence of publication bias. This meta-analysis suggests a favorable effect of statins on HCC, in the absence, however, of a duration-risk relationship. SN - 1473-5709 UR - https://www.unboundmedicine.com/medline/citation/23010949/Statins_and_primary_liver_cancer:_a_meta_analysis_of_observational_studies_ L2 - http://dx.doi.org/10.1097/CEJ.0b013e328358761a DB - PRIME DP - Unbound Medicine ER -